Drs. Martin Kampmann and Lisa Gunaydin, both Assistant Professors in the IND, celebrate being named Biohub investigators

IND faculty Dr. Lisa Gunaydin and Dr. Martin Kampmann were named Chan Zuckerberg Biohub Investigators. They are part of the first cohort of 47 scientists from UCSF, Stanford, and Berkeley to join the Biohub.

The Biohub is a nonprofit research organization with the goal to develop new technologies that transform biomedical research. It is funded by a philanthropic investment of $600 million by Facebook founder Mark Zuckerberg and pediatrician Priscilla Chan.

The Biohub is located... Read more ...

Vox AD CRISPR Kampmann


The Kampmann Lab's approach of using CRISPR to identify relevant genes, mechanisms, and therapeutic targets in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease was featured in a front page article on Vox. The article presents seven innovative ways in which CRISPR technology will make an impact in 2017.

Read the article...

Research is First to Suggest That Chronic Traumatic Encephalopathy is a Prion Disease

By Pete Farley (UCSF News Center) on December 02, 2016

A shared biological mechanism may drive the progression of both Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE), a neurodegenerative condition associated with repeated concussions and brain trauma, according to a new study led by UC San Francisco scientists.

Both AD and CTE are classified as “tauopathies,” a category of diseases characterized by the improper folding and clumping together of a protein called tau (rhymes with “how”) inside the nerve cells of the brain. The resulting tau aggregates, known as neurofibrillary tangles, are toxic to neurons and are thought to be responsible for the behavioral changes and cognitive decline seen in both disorders.

... Read more ...

Alzheimer UCSF prion tau Kampmann Chen

Postdoctoral fellow John Chen in the Kampmann lab received a Research Fellowship from the Alzheimer's Association. Together with Diane Nathaniel, Dr. Chen investigates cellular pathways controlling the prion-like spread of tau aggregation, which is emerging as a key driver of disease progression in Alzheimer's disease and other neurodegenerative diseases involving tau, including frontotemporal dementia. The Kampmann lab combines CRISPR-based genetic screens with biochemistry and cell biology. The pathways identified in this project are potential therapeutic targets in Alzheimer's disease and other tauopathies.